Park J - Search Results

1

Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects.

Choi JU, Kim JY, Chung SW, Lee NK, Park J, Kweon S, Cho YS, Kim HR, Lim SM, Park JW, Lee KC, Byun Y. Choi JU, et al. Among authors: park jw, park j. J Control Release. 2021 Aug 10;336:181-191. doi: 10.1016/j.jconrel.2021.06.019. Epub 2021 Jun 16. J Control Release. 2021. PMID: 34144107 Free article.

2

Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model.

Cui ZY, Park MJ, Lee J, Ahn JS, Ahn MJ, Seo SW, Park JW, Byun Y, Park K. Cui ZY, et al. Among authors: park mj, park jw, park k. Cancer Res Treat. 2009 Jun;41(2):80-6. doi: 10.4143/crt.2009.41.2.80. Epub 2009 Jun 30. Cancer Res Treat. 2009. PMID: 19707505 Free PMC article.

3

Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.

Park JW, Jeon OC, Kim SK, Al-Hilal TA, Moon HT, Kim CY, Byun Y. Park JW, et al. Mol Pharm. 2010 Jun 7;7(3):836-43. doi: 10.1021/mp900319k. Mol Pharm. 2010. PMID: 20349950

4

Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.

Eom JS, Koh KS, Al-Hilal TA, Park JW, Jeon OC, Moon HT, Byun Y. Eom JS, et al. Thromb Res. 2010 Sep;126(3):e220-4. doi: 10.1016/j.thromres.2010.06.001. Thromb Res. 2010. PMID: 20619883

5

High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.

Park JW, Jeon OC, Kim SK, Al-Hilal TA, Jin SJ, Moon HT, Yang VC, Kim SY, Byun Y. Park JW, et al. J Control Release. 2010 Dec 20;148(3):317-26. doi: 10.1016/j.jconrel.2010.09.014. Epub 2010 Sep 30. J Control Release. 2010. PMID: 20869408

6

Enhanced oral absorption of ibandronate via complex formation with bile acid derivative.

Park JW, Hwang SR, Jeon OC, Moon HT, Byun Y. Park JW, et al. J Pharm Sci. 2013 Feb;102(2):341-6. doi: 10.1002/jps.23413. Epub 2012 Dec 11. J Pharm Sci. 2013. PMID: 23233267

7

Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates.

Jeon OC, Hwang SR, Al-Hilal TA, Park JW, Moon HT, Lee S, Park JH, Byun Y. Jeon OC, et al. Pharm Res. 2013 Apr;30(4):959-67. doi: 10.1007/s11095-012-0932-0. Epub 2013 Jan 5. Pharm Res. 2013. PMID: 23292220

8

Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.

Park JW, Byun Y. Park JW, et al. Arch Pharm Res. 2014 Dec;37(12):1560-9. doi: 10.1007/s12272-013-0297-x. Epub 2013 Nov 20. Arch Pharm Res. 2014. PMID: 24254935

9

Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.

Al-Hilal TA, Park J, Alam F, Chung SW, Park JW, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Al-Hilal TA, et al. Among authors: park jw, park j. J Control Release. 2014 Feb 10;175:17-24. doi: 10.1016/j.jconrel.2013.12.001. Epub 2013 Dec 12. J Control Release. 2014. PMID: 24333628

10

Prevention effect of orally active heparin conjugate on cancer-associated thrombosis.

Al-Hilal TA, Alam F, Park JW, Kim K, Kwon IC, Ryu GH, Byun Y. Al-Hilal TA, et al. J Control Release. 2014 Dec 10;195:155-61. doi: 10.1016/j.jconrel.2014.05.027. Epub 2014 May 23. J Control Release. 2014. PMID: 24862320

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71,097 results

Search Page

Filters